Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases

Sung Yong Oh, Won Seog Kim, Seok Jin Kim, Jin Seok Kim, Sung Hyun Kim, Dae Ho Lee, Jong Ho Won, In Gyu Hwang, Min Kyoung Kim, Soon Il Lee, Jong Gwang Kim, Deok Hwan Yang, Hye Jin Kang, Chul Won Choi, Jinny Park, Young Jin Choi, Hyo Jung Kim, Jung Hye Kwon, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.

Original languageEnglish
Pages (from-to)826-829
Number of pages4
JournalAmerican Journal of Hematology
Issue number12
Publication statusPublished - 2009 Dec
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases'. Together they form a unique fingerprint.

Cite this